↓ Skip to main content

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial

Overview of attention for article published in Annals of the Rheumatic Diseases, May 2024
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
6 news outlets
blogs
1 blog
twitter
52 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Published in
Annals of the Rheumatic Diseases, May 2024
DOI 10.1136/ard-2024-225785
Pubmed ID
Authors

Weijia Wang, Shanzhi He, Wenli Zhang, Hongyu Zhang, Vincent M DeStefano, Masayuki Wada, Kevin Pinz, Greg Deener, Darshi Shah, Nabil Hagag, Min Wang, Ming Hong, Ronghao Zeng, Ting Lan, Yu Ma, Fugui Li, Yingwen Liang, Zhencong Guo, Chanjuan Zou, Mingxia Wang, Ling Ding, Yupo Ma, Yong Yuan

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 52 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 25%
Student > Doctoral Student 2 13%
Unspecified 2 13%
Lecturer 1 6%
Student > Ph. D. Student 1 6%
Other 3 19%
Unknown 3 19%
Readers by discipline Count As %
Medicine and Dentistry 4 25%
Immunology and Microbiology 3 19%
Unspecified 2 13%
Biochemistry, Genetics and Molecular Biology 2 13%
Business, Management and Accounting 1 6%
Other 1 6%
Unknown 3 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2024.
All research outputs
#588,993
of 26,238,951 outputs
Outputs from Annals of the Rheumatic Diseases
#238
of 7,798 outputs
Outputs of similar age
#9,070
of 330,253 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#3
of 45 outputs
Altmetric has tracked 26,238,951 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,798 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,253 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.